Just watched a video on MCL-1 and thought our group might be interested (if not already aware!).
From the CLL Society website:
As good as venetoclax is as a single agent, there are now many studies that show even more remarkable responses occur when it is used in combination with ibrutinib or rituximab. See this on the Murano trial from ASH 2017 that combined V+ rituximab. We soon will share the V+I data from ASCO 2018.
An MCL-1 inhibitor combo with V, if safe and tolerable, might seal the deal in CLL. Only time and trials will tell.
Here is my interview with my friend and CLL Society Medical Advisory board member, Dr. Rick Furman from ASH 2017
Watch this short video in plain language about MCL-1.